Fabry disease (FD) is a rare X-linked lysosomal storage disorder of glycosphingolipids, mostly globotriaosylceramide (Gb3). Proteinuric chronic kidney disease develops frequently, and recognition of Fabry nephropathy on a kidney biopsy may be the first clue to the underlying diagnosis. Since the accumulated glycosphingolipids are largely extracted by the paraffin-embedding procedure, the most characteristic feature of Fabry nephropathy on routine light microscopy (LM) is nonspecific cell vacuolization. To test whether residual Gb3 in kidney tissue might be exploited for the specific diagnosis of Fabry nephropathy, paraffin-embedded kidney biopsies of nine FD patients (one boy, four men, four women) and of a female carrier of a mild genetic mutation, with no evidence of Fabry nephropathy, were immunostained with an anti-Gb3 antibody. The adult biopsies were additionally co-stained with a lysosomal marker (anti-lysosomal-associated membrane protein 2 (anti-LAMP2) antibody). The distribution of Gb3 deposits was scored per cell type and compared to the histological scorings of glycosphingolipid inclusions on semi-thin sections. FD patients had residual Gb3 in all types of glomerular, tubular, interstitial and vascular kidney cells. The highest expression of LAMP2 was seen in tubular cells, but there were no meaningful associations between LAMP2 expression and prevalence of Gb3 deposits on different kidney cell types. The histological scorings of glycosphingolipid inclusions were relatively higher than the corresponding immunohistochemical scorings of Gb3 deposits. In the mildly affected female, Gb3 expression was limited to tubular cells, a pattern similar to controls. Gb3 immunostaining allows the specific diagnosis of Fabry nephropathy even in kidney biopsies routinely processed for LM.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-011-1182-yDOI Listing

Publication Analysis

Top Keywords

fabry nephropathy
24
diagnosis fabry
12
gb3 deposits
12
kidney
8
paraffin-embedded kidney
8
kidney tissue
8
gb3
8
nephropathy kidney
8
residual gb3
8
specific diagnosis
8

Similar Publications

Artificial intelligence (AI) is increasingly used in many medical specialties. However, nephrology has lagged in adopting and incorporating machine learning techniques. Nephrology is well positioned to capitalize on the benefits of AI.

View Article and Find Full Text PDF

Genetic Assessment of Living Kidney Transplant Donors: A Survey of Canadian Practices.

Can J Kidney Health Dis

January 2025

Multiorgan Transplant Program, Division of Nephrology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada.

Background: Kidney failure is a prevalent condition with tendency for familial clustering in up to 27% of the affected individuals. Living kidney donor (LKD) transplantation is the optimal treatment option; however, in Canada, more than 45% of LKDs are biologically related to their recipients which subjects recipients to worse graft survival and donors to higher future risk of kidney failure. Although not fully understood, this observation could be partially explained by genetic predisposition to kidney diseases.

View Article and Find Full Text PDF

Clinical management of female patients with Fabry disease based on expert consensus.

Orphanet J Rare Dis

January 2025

Department of Nephrology and Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Fabry disease is an X-linked lysosomal storage disorder that causes accumulation of glycosphingolipids in body tissues and fluids, leading to progressive organ damage and life-threatening complications. It can affect both males and females and can be classified into classic or later-onset phenotypes. The disease severity in females ranges from asymptomatic to the more severe, classic phenotype.

View Article and Find Full Text PDF

Background: Fabry disease is a rare X-linked multisystem disease, with progressive proteinuric kidney disease contributing significantly to morbidity and mortality of these patients. Evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2Is) can reduce proteinuria and slow progression to end-stage kidney disease in both diabetic and non-diabetic kidney disease.

Aim: Evaluate the effects of SGLT2I on kidney function and albuminuria in patients with Fabry disease.

View Article and Find Full Text PDF
Article Synopsis
  • Fabry disease can lead to chronic kidney disease (CKD) due to accumulated sphingolipids causing kidney damage, impacting treatment and prognostic planning.
  • In a study of 405 Fabry patients, significant findings included that 60.5% received treatments, 29.7% had cardiovascular events, and 3.3% reached end-stage kidney disease (ESKD), with men facing higher risks.
  • Key indicators for CKD development included older age, history of cardiovascular issues, specific medication use, and higher urine albumin-to-creatinine ratios, highlighting the need for monitoring even in patients with normal kidney function.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!